Kevin D. Dykstra
Merck & Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kevin D. Dykstra.
Angewandte Chemie | 2014
Daniel A. DiRocco; Kevin D. Dykstra; Shane W. Krska; Petr Vachal; Donald V. Conway; Matthew T. Tudge
The direct CH functionalization of heterocycles has become an increasingly valuable tool in modern drug discovery. However, the introduction of small alkyl groups, such as methyl, by this method has not been realized in the context of complex molecule synthesis since existing methods rely on the use of strong oxidants and elevated temperatures to generate the requisite radical species. Herein, we report the use of stable organic peroxides activated by visible-light photoredox catalysis to achieve the direct methyl-, ethyl-, and cyclopropylation of a variety of biologically active heterocycles. The simple protocol, mild reaction conditions, and unique tolerability of this method make it an important tool for drug discovery.
Bioorganic & Medicinal Chemistry Letters | 1999
Robert R. Wilkening; Ronald W. Ratcliffe; Kenneth J. Wildonger; Lovji D. Cama; Kevin D. Dykstra; Frank P. DiNinno; Timothy A. Blizzard; Milton L. Hammond; James V. Heck; Karen Dorso; E.St. Rose; Joyce Kohler; Gail G. Hammond
A series of 1beta-methyl carbapenems substituted at the 2-position with lipophilic, acyclic and cyclic (sulfonamido)methyl groups was prepared and evaluated for activity against resistant gram-positive bacteria. From these studies, the 1,8-naphthosultamyl group emerged as a novel, PBP2a-binding, anti-MRSA pharmacophore worthy of further exploration.
Journal of Organic Chemistry | 2016
Chelsea A. Huff; Ryan D. Cohen; Kevin D. Dykstra; Eric Streckfuss; Daniel A. DiRocco; Shane W. Krska
We report the development of a method for room-temperature C-H hydroxymethylation of heteroarenes. A key enabling advance in this work was achieved by implementing visible light photoredox catalysis that proved to be applicable to many classes of heteroarenes and tolerant of diverse functional groups found in druglike molecules.
Journal of Medicinal Chemistry | 2017
Tim Cernak; Nathan J. Gesmundo; Kevin D. Dykstra; Yang Yu; Zhicai Wu; Zhi-Cai Shi; Petr Vachal; Donald Mark Sperbeck; Shuwen He; Beth Ann Murphy; Lisa M. Sonatore; Steven Williams; Maria Madeira; Andreas Verras; Maud Reiter; Claire Lee; James Cuff; Edward C. Sherer; Jeffrey T. Kuethe; Stephen D. Goble; Nicholas Perrotto; Shirly Pinto; Dong-Ming Shen; Ravi P. Nargund; James M. Balkovec; Robert J. DeVita; Spencer D. Dreher
Miniaturization and parallel processing play an important role in the evolution of many technologies. We demonstrate the application of miniaturized high-throughput experimentation methods to resolve synthetic chemistry challenges on the frontlines of a lead optimization effort to develop diacylglycerol acyltransferase (DGAT1) inhibitors. Reactions were performed on ∼1 mg scale using glass microvials providing a miniaturized high-throughput experimentation capability that was used to study a challenging SNAr reaction. The availability of robust synthetic chemistry conditions discovered in these miniaturized investigations enabled the development of structure-activity relationships that ultimately led to the discovery of soluble, selective, and potent inhibitors of DGAT1.
ACS Medicinal Chemistry Letters | 2014
Shuwen He; Qingmei Hong; Zhong Lai; David X. Yang; Pauline C. Ting; Jeffrey T. Kuethe; Timothy A. Cernak; Kevin D. Dykstra; Donald M. Sperbeck; Zhicai Wu; Yang Yu; Ginger X. Yang; Tianying Jian; Jian Liu; Deodial Guiadeen; Arto D. Krikorian; Lisa M. Sonatore; Judyann Wiltsie; Jinqi Liu; Judith N. Gorski; Christine C. Chung; Jack Gibson; JeanMarie Lisnock; Jianying Xiao; Michael Wolff; Sharon Tong; Maria Madeira; Bindhu V. Karanam; Dong-Ming Shen; James M. Balkovec
We report the discovery of a novel series of DGAT1 inhibitors in the benzimidazole class with a piperdinyl-oxy-cyclohexanecarboxylic acid moiety. This novel series possesses significantly improved selectivity against the A2A receptor, no ACAT1 off-target activity at 10 μM, and higher aqueous solubility and free fraction in plasma as compared to the previously reported pyridyl-oxy-cyclohexanecarboxylic acid series. In particular, 5B was shown to possess an excellent selectivity profile by screening it against a panel of more than 100 biological targets. Compound 5B significantly reduces lipid excursion in LTT in mouse and rat, demonstrates DGAT1 mediated reduction of food intake and body weight in mice, is negative in a 3-strain Ames test, and appears to distribute preferentially in the liver and the intestine in mice. We believe this lead series possesses significant potential to identify optimized compounds for clinical development.
Tetrahedron Letters | 1998
Kevin D. Dykstra; Frank P. DiNinno
Abstract The Stille cross-coupling reaction is an extremely mild and versatile method for the coupling of organostannanes with vinyl triflates. This methodology has been extended to include functionalized 2-alkenyl and alkynyl-1-β-methylcarbapenems.
Journal of Chemical Information and Modeling | 2015
Sriram Tyagarajan; Christopher T. Lowden; Zhengwei Peng; Kevin D. Dykstra; Edward C. Sherer; Shane W. Krska
We report the development and implementation of a cheminformatics tool which aids in the design of compounds during exploratory chemistry and lead optimization. The Heterocyclic Regioisomer Enumeration and MDDR Search (HREMS) tool allows medicinal chemists to build greater structural diversity into their synthetic planning by enabling a systematic, automated enumeration of heterocyclic regioisomers of target structures. To help chemists overcome biases arising from past experience or synthetic accessibility, the HREMS tool further provides statistics on clinical testing for each enumerated regioisomer substructure using an automated search of a commercial database. Ready access to this type of information can help chemists make informed choices on the targets they will pursue being mindful of past experience with these structures in drug development. This tool and its components can be incorporated into other cheminformatics workflows to leverage their capabilities in triaging and in silico compound enumeration.
Chemical Society Reviews | 2016
Tim Cernak; Kevin D. Dykstra; Sriram Tyagarajan; Petr Vachal; Shane W. Krska
Bioorganic & Medicinal Chemistry Letters | 2004
Helen Chen; Kevin D. Dykstra; Elizabeth T. Birzin; Katalin Frisch; Wanda Chan; Yi T. Yang; Ralph T. Mosley; Frank P. DiNinno; Susan P. Rohrer; James M. Schaeffer; Milton L. Hammond
Chemical Science | 2016
Peter S. Kutchukian; James F. Dropinski; Kevin D. Dykstra; Bing Li; Daniel A. DiRocco; Eric Streckfuss; Louis-Charles Campeau; Tim Cernak; Petr Vachal; Ian W. Davies; Shane W. Krska; Spencer D. Dreher